755:
retinopathy, visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO), and visual impairment due to choroidal neovascularization. The applicant for this medicinal product is QILU PHARMA SPAIN S.L. Rimmyrah is a biosimilar medicinal product that is highly similar to the reference product
Lucentis (ranibizumab), which was authorized in the EU in January 2007. Rimmyrah was approved for medical use in the European Union in January 2024.
744:(EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Ranivisio, intended for the treatment of neovascular (wet) age-related macular degeneration, visual impairment due to macular edema or choroidal neovascularization, and proliferative diabetic retinopathy. The applicant for this medicinal product is Midas Pharma GmbH. Ranivisio was approved for medical use in the European Union in August 2022.
782:
only 337,000 injections. A small study showed no superior effect of ranibizumab versus bevacizumab in direct comparison. The initial results of the larger
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) found that the two drugs "had equivalent effects on visual acuity when administered according to the same schedule;" however, serious adverse events were more common in the bevacizumab arm of the trial.
6416:
1456:
1927:
2106:
751:
retinopathy, visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO), and visual impairment due to choroidal neovascularization. The applicant for this medicinal product is STADA Arzneimittel AG. Ximluci was approved for medical use in the
European Union in November 2022.
766:
diabetic retinopathy, visual impairment due to macular edema secondary to retinal vein occlusion and visual impairment due to choroidal neovascularization. The applicant for this medicinal product is Midas Pharma GmbH. Ranibizumab Midas is a biosimilar medicinal product and is a duplicate of
Ranivisio.
781:
Genentech offered secret rebates to about 300 ophthalmologists in an apparent inducement to get them to use more ranibizumab rather than the less expensive bevacizumab. In 2008, bevacizumab cost
Medicare only $ 20 million for about 480,000 injections, while ranibizumab cost Medicare $ 537 million for
754:
In
November 2023, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Rimmyrah, intended for the treatment of neovascular (wet) age-related macular degeneration, visual impairment due to diabetic macular edema, proliferative diabetic
750:
In
September 2022, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Ximluci, intended for the treatment of neovascular (wet) age-related macular degeneration, visual impairment due to diabetic macular edema, proliferative diabetic
765:
In July 2024, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product
Ranibizumab Midas, intended for the treatment of neovascular (wet) age-related macular degeneration, visual impairment due to diabetic macular edema, proliferative
617:
In the
European Union, ranibizumab is indicated for the treatment of neovascular (wet) age-related macular degeneration, visual impairment due to diabetic macular edema, proliferative diabetic retinopathy, visual impairment due to macular edema secondary to retinal vein occlusion, and visual
2102:
785:
According to a 2012 meta-analysis, the results of several subsequent head-to-head trials found that the two therapies performed equally at restoring visual acuity. A 2012 meta-analysis focused specifically on safety issues concluded that the rates of several adverse events were higher with
2452:
2884:
648:
A 2014 Cochrane review did not find a difference between bevacizumab and ranibizumab in deaths or total severe side effects when used for macular degeneration. There, however, was not a lot of evidence, and thus this conclusion is not that certain.
2442:
2877:
1441:
2870:
2325:
613:
for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
758:
In
January 2024, Sandoz signed an agreement to acquire ranibizumab-eqrn, the biosimilar version of ranibizumab branded as Cimerli from Coherus BioSciences, Inc. for an upfront cash purchase payment of
786:
bevacizumab, although the absolute rates of ocular serious adverse events were low with both therapies: ocular adverse events were about 2.8 times as frequent with bevacizumab than with ranibizumab.
2295:
2103:"FDA Approves Coherus' Cimerli (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis for All Five Indications, with 12 Months of Interchangeability Exclusivity"
2265:
261:
5693:
1188:
1763:
1429:
5713:
1253:
1031:
893:
818:
5703:
3482:
3858:
2780:
2317:
778:. Its rates of side effects also appear similar. However, ranibizumab typically costs $ 2,000 a dose, while the equivalent dose of bevacizumab typically costs $ 50.
601:, under the brand name Lucentis. Ranibizumab (Lucentis) was approved for medical use in the United States in June 2006, and in the European Union in January 2007.
1404:
640:
Susvimo is a reformulation of ranibizumab suitable for injection via ocular implant. Susvimo was approved for medical use in the United States in October 2021.
5688:
216:
667:. Other serious ocular adverse events observed among ranibizumab-treated patients (incidence rate < 1%) included intraocular inflammation and blindness.
4223:
652:
Ranibizumab does appear to result in a lower risk of stomach and intestinal problems. It is also associated with a low rate of eye related side effects.
2287:
1359:
530:
2049:
2208:
2173:
2080:
1986:
2142:
5458:
3533:
5397:
4574:
3766:
3475:
6357:
4499:
1956:
737:
2674:"Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab"
2369:
Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
2221:
Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
2155:
Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
2062:
Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
1334:
1299:
Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
1079:
Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
946:
Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
868:
Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
6446:
6081:
5994:
5939:
5893:
5838:
5573:
5513:
4514:
4444:
4003:
3601:
3543:
3314:
2773:
2723:"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial"
114:
2633:"Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial"
2257:
2016:
6076:
5954:
5853:
5639:
5528:
5328:
5288:
5036:
4955:
4817:
4758:
4720:
4665:
4660:
4650:
4524:
4519:
4489:
4464:
4459:
4449:
4335:
4254:
4193:
4121:
4100:
4085:
4038:
3691:
6176:
6034:
6013:
5969:
5949:
5868:
5848:
5563:
5543:
5523:
5166:
5161:
4494:
4218:
3751:
3548:
933:
1286:
637:, there is low-certainty evidence suggesting that ranibizumab is more effective in reducing central retinal thickness than bevacizumab.
5999:
5989:
5944:
5898:
5888:
5843:
5667:
5634:
5614:
5578:
5568:
5518:
5478:
4950:
4930:
4897:
4778:
4680:
4529:
3468:
1726:
1180:
1066:
855:
5959:
5858:
5753:
5657:
5609:
5602:
5588:
5533:
5503:
4983:
4973:
4925:
4907:
4836:
4670:
4509:
4454:
1751:
47:
5698:
5388:
2766:
2609:
2721:
Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. (IVAN study investigators) (October 2013).
4993:
4710:
1245:
1100:
1023:
885:
810:
5798:
3978:
3661:
2527:
6441:
6376:
6326:
6297:
6244:
4731:
4598:
3426:
2862:
1909:
967:
6456:
6055:
6051:
6047:
6043:
3596:
3580:
692:
622:
81:
4324:
4243:
4110:
4027:
1924:
6039:
1311:"Intravitreal Ranibizumab for Choroidal Neovascularization in Best's Vitelliform Macular Dystrophy in a 6-Year-Old Boy"
655:
Serious adverse events related to the injection procedure occurred with an incidence rate of less than 1% and included
537:
165:
1392:
633:. A 2023 systematic review update found that while ranibizumab and bevacizumab provide similar functional outcomes in
5728:
4847:
4407:
4018:
1792:
Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, et al. (September 2014). Moja L (ed.).
1666:
Virgili G, Curran K, Lucenteforte E, Peto T, Parravano M, et al. (Cochrane Eyes and Vision Group) (June 2023).
6436:
3676:
3620:
3611:
3443:
6250:
246:
146:
6451:
6337:
6313:
5453:
5009:
4872:
587:
6303:
1367:
583:
2758:
109:
Byooviz, Cimerli, Ranivisio, Raniviz, Ranopto, Rimmyrah, Susvimo, Ximluci ranibizumab-eqrn, ranibizumab-nuna
6461:
6347:
4743:
4625:
4615:
2957:
2807:
2551:"Switching to less expensive blindness drug could save medicare part B $ 18 billion over a ten-year period"
2041:
1757:
1435:
1398:
407:
2288:"Sandoz announces agreement to acquire Cimerli business from Coherus, strengthening position in US market"
2231:
2200:
2165:
2072:
1978:
1519:"A clearer view of evidence in treating macular degeneration: off-label policies and independent research"
456:
5718:
2893:
2131:
1152:"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)"
209:
1210:
6406:
6332:
4158:
2352:
6240:
2136:
1151:
927:
741:
1948:
1794:"Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration"
59:
4424:
4340:
4259:
4126:
4043:
3082:
3077:
1310:
559:
17:
6024:
3771:
3646:
3431:
2384:"A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard"
2008:
1843:"A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard"
1617:
Sarwar S, Clearfield E, Soliman MK, Sadiq MA, Baldwin AJ, Hanout M, et al. (February 2016).
202:
94:
726:
Ranibizumab-nuna (Byooviz) was approved for medical use in the United States in September 2021.
6308:
5924:
5828:
5448:
4867:
3853:
3491:
3338:
2892:
1668:"Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis"
1430:"FDA Approves First Biosimilar to Treat Macular Degeneration Disease and Other Eye Conditions"
922:
6466:
6382:
4579:
3863:
3502:
1278:
992:
747:
Ranibizumab-eqrn (Cimerli) was approved for medical use in the United States in August 2022.
2443:"An effective eye drug is available for $ 50. But many doctors choose a $ 2,000 alternative"
1715:
1058:
847:
360:
6322:
5708:
4640:
4589:
2631:
Subramanian ML, Abedi G, Ness S, Ahmed E, Fenberg M, Daly MK, et al. (November 2010).
2395:
1854:
634:
575:
571:
416:
333:
1570:"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration"
8:
5463:
4877:
2599:
2447:
2382:
Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, et al. (2012).
1841:
Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, et al. (2012).
684:
555:
351:
40:
2399:
1858:
1692:
1667:
1545:
1518:
5141:
3494:
3216:
3115:
2986:
2703:
2604:
2575:
2550:
2503:
2478:
2418:
2383:
1877:
1842:
1818:
1793:
1643:
1618:
1594:
1569:
1491:
1474:
660:
176:
2739:
2722:
5768:
2793:
2744:
2695:
2654:
2580:
2508:
2423:
1905:
1882:
1823:
1697:
1648:
1599:
1550:
1496:
1326:
1092:
290:
273:
138:
3460:
2707:
6186:
5318:
3123:
2734:
2685:
2644:
2570:
2562:
2535:
2498:
2490:
2413:
2403:
1872:
1862:
1813:
1809:
1805:
1687:
1683:
1679:
1638:
1634:
1630:
1589:
1585:
1581:
1540:
1530:
1486:
1318:
567:
472:
325:
229:
124:
1125:
959:
6420:
2408:
1931:
1867:
1322:
656:
2797:
6372:
6293:
6235:
5929:
5778:
5773:
4887:
4882:
3528:
3518:
3513:
3437:
3092:
2566:
2479:"Ranibizumab and bevacizumab for neovascular age-related macular degeneration"
1535:
6430:
6066:
5979:
5908:
5878:
5813:
5723:
5677:
5553:
5483:
5428:
5417:
4902:
4610:
4293:
4198:
4090:
3408:
3367:
3177:
3011:
2789:
2788:
1460:
730:
579:
303:
1904:(in German) (2009/2010 ed.). Vienna: Österreichischer Apothekerverlag.
1568:
Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS (August 2014).
1309:
Heidary F, Hitam WH, Ngah NF, George TM, Hashim H, Shatriah I (March 2011).
33:
6392:
6362:
6101:
6091:
5984:
5883:
5738:
5558:
5493:
5408:
4912:
4715:
4554:
4549:
4469:
4419:
4233:
3987:
3968:
3947:
3918:
3641:
3636:
3403:
3294:
3289:
3274:
3231:
3172:
3162:
3147:
3142:
2831:
2748:
2699:
2658:
2584:
2512:
2477:
Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (May 2011).
2427:
1886:
1827:
1701:
1652:
1603:
1554:
1500:
1473:
Ramin S, Soheilian M, Habibi G, Ghazavi R, Gharebaghi R, Heidary F (2015).
1330:
723:
Byooviz was approved for medical use in the European Union in August 2021.
688:
224:
52:
2494:
6352:
6318:
6216:
6201:
6191:
6141:
5964:
5863:
5624:
5538:
5468:
5363:
5126:
5091:
5041:
5004:
4940:
4822:
4753:
4705:
4695:
4690:
4685:
4569:
4564:
4559:
3937:
3848:
3838:
3806:
3801:
3796:
3791:
3781:
3741:
3706:
3387:
3319:
3309:
3284:
3187:
3182:
3137:
3128:
3105:
3056:
3016:
2943:
2851:
2826:
2816:
2649:
2632:
2258:"FDA Approves Ranibizumab-eqrn Biosimilar, Interchangeable with Lucentis"
1517:
Formoso G, Marata AM, Magrini N, Bero L (September 2014). Tovey D (ed.).
775:
718:
696:
630:
626:
563:
132:
380:
6171:
6136:
6131:
6121:
6111:
6029:
5818:
5793:
5783:
5629:
5583:
5443:
5269:
5238:
5207:
5176:
5121:
5096:
5076:
5061:
5051:
4945:
4862:
4655:
4635:
4534:
4479:
4474:
4298:
4203:
4188:
3983:
3942:
3914:
3883:
3843:
3746:
3701:
3696:
3671:
3666:
3656:
3569:
3563:
3553:
3382:
3299:
3279:
3258:
3253:
3221:
3157:
3152:
3046:
3041:
3031:
3026:
3021:
3006:
3001:
2972:
2938:
2841:
2821:
2690:
2673:
511:
391:
104:
6196:
6166:
6161:
6156:
6151:
6146:
6126:
6116:
6106:
6096:
5788:
5748:
5644:
5619:
5378:
5373:
5368:
5358:
5353:
5348:
5338:
5259:
5197:
5131:
5111:
5106:
5101:
5086:
5081:
5071:
5066:
4960:
4935:
4700:
4620:
4539:
4484:
4374:
4313:
4303:
4208:
4095:
3893:
3888:
3878:
3786:
3776:
3761:
3736:
3731:
3721:
3716:
3711:
3324:
3304:
3248:
3236:
3226:
3201:
3167:
3100:
3061:
3051:
3036:
2922:
2917:
2836:
610:
594:
118:
64:
6367:
6086:
5743:
5343:
5333:
5313:
5056:
5046:
4393:
3873:
3816:
3726:
3686:
3243:
2009:"Lupin receives CDSCO committee approval for marketing ranibizumab"
664:
598:
436:
371:
160:
5248:
5217:
5186:
5150:
2549:
Hutton D, Newman-Casey PA, Tavag M, Zacks D, Stein J (June 2014).
6342:
5763:
5228:
4630:
3591:
2036:
2034:
1459:
This article incorporates text from this source, which is in the
1387:
1385:
76:
2195:
2193:
2191:
6255:
5919:
5808:
5733:
5438:
5433:
4857:
4852:
4806:
4802:
4798:
4794:
4790:
4786:
4782:
4434:
3973:
3651:
2720:
2126:
2124:
1567:
1479:
Medical Hypothesis, Discovery & Innovation in Ophthalmology
733:
received marketing approval for its biosimilar of Ranibizumab.
447:
2896:
for bone, musculoskeletal, circulatory, and neurologic systems
2031:
1619:"Aflibercept for neovascular age-related macular degeneration"
1382:
6287:
6283:
6279:
6275:
6271:
6267:
6263:
6259:
5974:
5873:
5548:
5488:
5302:
5025:
5021:
5017:
5013:
4504:
4368:
4287:
4283:
4182:
4178:
4174:
4170:
4079:
4075:
3926:
2188:
1665:
68:
2548:
2381:
2121:
1840:
1616:
1475:"Age-Related Macular Degeneration: A Scientometric Analysis"
597:
and marketed by them in the United States, and elsewhere by
5758:
4364:
4360:
4356:
4352:
4348:
4344:
4279:
4275:
4271:
4267:
4263:
4166:
4162:
4154:
4150:
4146:
4142:
4138:
4134:
4130:
4071:
4067:
4063:
4059:
4055:
4051:
4047:
3999:
3995:
3991:
3957:
3922:
3903:
2902:
2528:"Switch From Lucentis to Avastin Could Save Medicare $ 18B"
1791:
1472:
1393:"Drug Approval Package: Lucentis (Ranibizumab) NDA #125156"
427:
2630:
2476:
2347:
2345:
2343:
1159:
1516:
570:
that is approved to treat the "wet" type of age-related
6358:
Pituitary adenylate cyclase-activating peptide (PACAP)
2340:
1354:
1352:
1308:
6404:
3490:
2105:(Press release). Coherus BioSciences. 2 August 2022.
1240:
1238:
1236:
1234:
1232:
1087:
1085:
1144:
1349:
1018:
1016:
1014:
880:
878:
876:
874:
805:
803:
801:
799:
6304:Glucose-6-phosphate isomerase (GPI; PGI, PHI, AMF)
5162:Glial cell line-derived neurotrophic factor (GDNF)
4815:Cleavage products/derivatives with unknown target:
1424:
1422:
1229:
1082:
2318:"Sandoz: acquisition of ophthalmology biosimilar"
1315:Journal of Pediatric Ophthalmology and Strabismus
562:) created from the same parent mouse antibody as
6428:
6338:Macrophage-stimulating protein (MSP; HLP, HGFLP)
2440:
2377:
2375:
1273:
1271:
1120:
1118:
1011:
917:
915:
913:
911:
871:
796:
618:impairment due to choroidal neovascularisation.
3979:Heparin-binding EGF-like growth factor (HB-EGF)
3662:Heparin-binding EGF-like growth factor (HB-EGF)
2671:
1419:
987:
985:
954:
952:
886:"Cimerli- ranibizumab-eqrn injection, solution"
811:"Byooviz Nuna- ranibizumab injection, solution"
359:
2600:"Genentech Offers Secret Rebates for Eye Drug"
1053:
1051:
1049:
842:
840:
838:
836:
738:Committee for Medicinal Products for Human Use
6390:Additional growth factor receptor modulators:
3476:
2878:
2774:
2678:Journal of Clinical Pharmacy and Therapeutics
2542:
2372:
1268:
1115:
908:
4744:Insulin-like growth factor-2 (somatomedin A)
4626:Insulin-like growth factor-2 (somatomedin A)
4616:Insulin-like growth factor-1 (somatomedin C)
1893:
982:
949:
164:
2224:
1798:The Cochrane Database of Systematic Reviews
1787:
1785:
1783:
1781:
1672:The Cochrane Database of Systematic Reviews
1623:The Cochrane Database of Systematic Reviews
1574:The Cochrane Database of Systematic Reviews
1523:The Cochrane Database of Systematic Reviews
1246:"Lucentis- ranibizumab injection, solution"
1046:
833:
3483:
3469:
2885:
2871:
2781:
2767:
2441:Whoriskey P, Keating D (7 December 2013).
1512:
1510:
1024:"Susvimo- ranibizumab injection, solution"
625:. Its effectiveness is similar to that of
2738:
2689:
2665:
2648:
2574:
2525:
2502:
2417:
2407:
1899:
1876:
1866:
1817:
1691:
1642:
1593:
1544:
1534:
1490:
415:
6348:Migration-stimulating factor (MSF; PRG4)
3346:
2714:
2672:Jiang S, Park C, Barner JC (June 2014).
1918:
1778:
774:Its effectiveness is similar to that of
3677:Transforming growth factor alpha (TGFα)
2597:
2472:
2470:
1507:
1211:"Summary Basis of Decision for Ranopto"
675:No significant interactions are known.
379:
137:
14:
6429:
6251:Connective tissue growth factor (CTGF)
2145:from the original on 19 September 2022
1610:
1444:from the original on 20 September 2021
1289:from the original on 10 September 2021
1256:from the original on 21 September 2021
1191:from the original on 29 September 2022
1130:Therapeutic Goods Administration (TGA)
1103:from the original on 21 September 2021
1097:Therapeutic Goods Administration (TGA)
964:Therapeutic Goods Administration (TGA)
858:from the original on 10 September 2021
702:
312:
284:
6314:Hepatoma-derived growth factor (HDGF)
3464:
2866:
2762:
2268:from the original on 19 February 2023
2211:from the original on 13 November 2023
2176:from the original on 17 November 2022
2019:from the original on 24 November 2021
1181:"Summary Basis of Decision - Byooviz"
1034:from the original on 19 December 2021
609:In the United States, ranibizumab is
455:
297:
155:
123:
6447:Drugs developed by Hoffmann-La Roche
2965:
2612:from the original on 9 November 2020
2467:
2455:from the original on 26 January 2021
2298:from the original on 29 January 2024
2236:Union Register of medicinal products
2170:Union Register of medicinal products
2117:– via GlobeNewswire News Room.
2077:Union Register of medicinal products
1983:Union Register of medicinal products
1440:(Press release). 20 September 2021.
970:from the original on 8 February 2024
896:from the original on 21 January 2023
693:vascular endothelial growth factor A
623:age-related wet macular degeneration
228:
82:Vascular endothelial growth factor A
2483:The New England Journal of Medicine
1337:from the original on 1 October 2021
936:from the original on 6 October 2022
435:
24:
2434:
2328:from the original on 10 March 2024
2109:from the original on 3 August 2022
1959:from the original on 30 March 2015
1766:from the original on 3 August 2022
1407:from the original on 2 August 2022
1069:from the original on 13 March 2023
821:from the original on 3 August 2022
25:
6478:
2083:from the original on 3 March 2023
2052:from the original on 26 June 2022
1989:from the original on 3 March 2023
1732:from the original on 13 July 2024
1716:"Susvimo Prescribing Information"
695:, a mechanism similar to that of
255:
187:
6414:
6333:Leukemia inhibitory factor (LIF)
2042:"Ranivisio: Pending EC decision"
1454:
489:
483:
5501:Negative allosteric modulators:
2624:
2591:
2519:
2310:
2280:
2250:
2201:"Rimmyrah: Pending EC decision"
2158:
2095:
2073:"Ranivisio Product information"
2065:
2001:
1971:
1941:
1834:
1744:
1708:
1659:
1561:
1466:
1302:
1215:Drug and Health Products Portal
1203:
1173:
997:European Medicines Agency (EMA)
707:
678:
670:
643:
604:
5819:Gossypetin (3,5,7,8,3',4'-HHF)
5010:Platelet-derived growth factor
2132:"Ximluci: Pending EC decision"
1810:10.1002/14651858.CD011230.pub2
1684:10.1002/14651858.CD007419.pub7
1635:10.1002/14651858.CD011346.pub2
1586:10.1002/14651858.CD005139.pub3
712:
588:central retinal vein occlusion
501:
495:
477:
268:
13:
1:
6025:Placental growth factor (PGF)
2740:10.1016/S0140-6736(13)61501-9
2598:Pollack A (3 November 2010).
2166:"Ximluci Product information"
1979:"Byooviz Product information"
1752:"Susvimo: FDA-Approved Drugs"
789:
593:Ranibizumab was developed by
584:branch retinal vein occlusion
6442:Drugs developed by Genentech
6309:Glia maturation factor (GMF)
4818:Glypromate (GPE, (1-3)IGF-1)
2526:Henderson D (17 June 2014).
2409:10.1371/journal.pone.0042701
1868:10.1371/journal.pone.0042701
1758:Food and Drug Administration
1436:Food and Drug Administration
1399:Food and Drug Administration
1323:10.3928/01913913-20110308-02
769:
550:, sold under the brand name
7:
6457:Drugs developed by Novartis
10:
6483:
6241:Colony-stimulating factors
6233:Additional growth factors:
1317:. 48 Online (6): e19–e22.
716:
467:Chemical and physical data
6225:
6012:
5907:
5676:
5589:SNA-120 (pegylated K252a)
5416:
5407:
5387:
5301:
5278:
5247:
5216:
5185:
5149:
5140:
4992:
4835:
4768:
4761:(against IGF-1 and IGF-2)
4730:
4723:(against IGF-1 and IGF-2)
4597:
4588:
4406:
4383:
4323:
4242:
4109:
4026:
4017:
3956:
3902:
3815:
3619:
3610:
3579:
3501:
3421:
3396:
3375:
3366:
3337:
3267:
3209:
3200:
3114:
3091:
3070:
2994:
2985:
2956:
2931:
2910:
2901:
2805:
2567:10.1377/hlthaff.2013.0832
2357:European Medicines Agency
2205:European Medicines Agency
2137:European Medicines Agency
2046:European Medicines Agency
1900:Haberfeld H, ed. (2009).
1536:10.1002/14651858.ED000090
1283:European Medicines Agency
1063:European Medicines Agency
928:European Medicines Agency
852:European Medicines Agency
742:European Medicines Agency
527:
510:
471:
466:
446:
426:
406:
390:
370:
350:
345:
332:
324:
245:
240:
215:
201:
175:
145:
131:
113:
103:
93:
88:
75:
58:
46:
39:
4425:Hepatocyte growth factor
3984:Neuregulins (heregulins)
3915:Neuregulins (heregulins)
3859:Trastuzumab duocarmazine
3572:(against angiopoietin 2)
3566:(against angiopoietin 3)
2353:"Ranibizumab Midas EPAR"
6437:Angiogenesis inhibitors
3772:Depatuxizumab mafodotin
6395:(neurotrophin mixture)
6383:Wnt signaling proteins
6064:Allosteric modulators:
5784:Norwogonin (5,7,8-THF)
4004:5 (tomoregulin, TMEFF)
3854:Trastuzumab deruxtecan
3492:Growth factor receptor
3339:Angiogenesis inhibitor
1938:Lexi-Comp, Inc.; 2007.
1930:29 August 2021 at the
635:diabetic macular edema
210:Intravitreal injection
6452:Monoclonal antibodies
6323:T-cell growth factors
4580:Telisotuzumab vedotin
3864:Trastuzumab emtansine
2495:10.1056/NEJMoa1102673
2141:. 15 September 2022.
1403:. 26 September 2006.
1360:"Lucentis Fact Sheet"
1285:. 17 September 2018.
1093:"AusPAR: Ranibizumab"
1065:. 14 September 2022.
4908:EVT-901 (SAR-127963)
4641:Mecasermin rinfabate
2650:10.1038/eye.2010.147
2207:. 10 November 2023.
576:diabetic retinopathy
572:macular degeneration
6462:Ophthalmology drugs
2733:(9900): 1258–1267.
2448:The Washington Post
2400:2012PLoSO...742701S
2324:. 22 January 2024.
1859:2012PLoSO...742701S
1099:. 9 December 2014.
892:. 19 October 2022.
703:Society and culture
685:monoclonal antibody
556:monoclonal antibody
554:among others, is a
293:(Prescription only)
264:(Prescription only)
41:Monoclonal antibody
36:
27:Pharmaceutical drug
6074:Kinase inhibitors:
5937:Kinase inhibitors:
5836:Kinase inhibitors:
5511:Kinase inhibitors:
5326:Kinase inhibitors:
5286:Kinase inhibitors:
5267:Kinase inhibitors:
5236:Kinase inhibitors:
5205:Kinase inhibitors:
5174:Kinase inhibitors:
5034:Kinase inhibitors:
4648:Kinase inhibitors:
4442:Kinase inhibitors:
4231:Kinase inhibitors:
4224:Aprutumab ixadotin
3871:Kinase inhibitors:
3684:Kinase inhibitors:
3541:Kinase inhibitors:
3448:Never to phase III
3217:Anti-amyloid drugs
2808:neovascularisation
2691:10.1111/jcpt.12146
2605:The New York Times
2538:on 29 August 2021.
1370:on 28 October 2012
1217:. 1 September 2012
1187:. 12 August 2022.
1132:. 6 September 2022
966:. 8 January 2024.
736:In June 2022, the
661:retinal detachment
574:(AMD, also ARMD),
32:
6402:
6401:
6008:
6007:
5769:N-Acetylserotonin
5668:ReN-1820 (TrkAd5)
5297:
5296:
4831:
4830:
4776:Binding proteins:
4435:Dihexa (PNB-0408)
4402:
4401:
4013:
4012:
3927:6 (neuroglycan C)
3647:EGF (urogastrone)
3625:
3458:
3457:
3417:
3416:
3362:
3361:
3333:
3332:
3196:
3195:
2981:
2980:
2952:
2951:
2860:
2859:
2794:vascular disorder
2790:Ophthalmologicals
2643:(11): 1708–1715.
2489:(20): 1897–1908.
2294:(Press release).
2264:. 3 August 2022.
2013:www.pharmabiz.com
1911:978-3-85200-196-8
817:. 27 April 2022.
683:Ranibizumab is a
545:
544:
316:
301:
288:
271:
259:
191:
158:
16:(Redirected from
6474:
6419:
6418:
6417:
6410:
6214:Decoy receptors:
6187:Alacizumab pegol
5665:Decoy receptors:
5414:
5413:
5319:Stem cell factor
5260:Persephin (PSPN)
5198:Neurturin (NRTN)
5147:
5146:
4984:LEVI-04 (p75-Fc)
4981:Decoy receptors:
4595:
4594:
4024:
4023:
3623:
3617:
3616:
3485:
3478:
3471:
3462:
3461:
3373:
3372:
3344:
3343:
3207:
3206:
3124:Alacizumab pegol
2992:
2991:
2963:
2962:
2908:
2907:
2887:
2880:
2873:
2864:
2863:
2783:
2776:
2769:
2760:
2759:
2753:
2752:
2742:
2718:
2712:
2711:
2693:
2669:
2663:
2662:
2652:
2628:
2622:
2621:
2619:
2617:
2595:
2589:
2588:
2578:
2546:
2540:
2539:
2534:. Archived from
2523:
2517:
2516:
2506:
2474:
2465:
2464:
2462:
2460:
2438:
2432:
2431:
2421:
2411:
2379:
2370:
2368:
2366:
2364:
2349:
2338:
2337:
2335:
2333:
2314:
2308:
2307:
2305:
2303:
2284:
2278:
2277:
2275:
2273:
2254:
2248:
2247:
2245:
2243:
2238:. 9 January 2024
2228:
2222:
2220:
2218:
2216:
2197:
2186:
2185:
2183:
2181:
2162:
2156:
2154:
2152:
2150:
2128:
2119:
2118:
2116:
2114:
2099:
2093:
2092:
2090:
2088:
2069:
2063:
2061:
2059:
2057:
2048:. 22 June 2022.
2038:
2029:
2028:
2026:
2024:
2005:
1999:
1998:
1996:
1994:
1975:
1969:
1968:
1966:
1964:
1945:
1939:
1922:
1916:
1915:
1897:
1891:
1890:
1880:
1870:
1838:
1832:
1831:
1821:
1789:
1776:
1775:
1773:
1771:
1748:
1742:
1741:
1739:
1737:
1731:
1720:
1712:
1706:
1705:
1695:
1663:
1657:
1656:
1646:
1614:
1608:
1607:
1597:
1565:
1559:
1558:
1548:
1538:
1514:
1505:
1504:
1494:
1470:
1464:
1458:
1457:
1453:
1451:
1449:
1426:
1417:
1416:
1414:
1412:
1389:
1380:
1379:
1377:
1375:
1366:. Archived from
1356:
1347:
1346:
1344:
1342:
1306:
1300:
1298:
1296:
1294:
1275:
1266:
1265:
1263:
1261:
1242:
1227:
1226:
1224:
1222:
1207:
1201:
1200:
1198:
1196:
1177:
1171:
1170:
1168:
1166:
1156:nctr-crs.fda.gov
1148:
1142:
1141:
1139:
1137:
1122:
1113:
1112:
1110:
1108:
1089:
1080:
1078:
1076:
1074:
1055:
1044:
1043:
1041:
1039:
1020:
1009:
1008:
1006:
1004:
999:. 5 January 2024
989:
980:
979:
977:
975:
956:
947:
945:
943:
941:
932:. 20 June 2022.
923:"Ranivisio EPAR"
919:
906:
905:
903:
901:
882:
869:
867:
865:
863:
854:. 23 June 2021.
844:
831:
830:
828:
826:
807:
761:
663:, and traumatic
541:
540:
533:
522:
520:
503:
497:
491:
485:
479:
459:
439:
419:
383:
363:
337:
314:
311:
306:
299:
296:
286:
283:
279:
270:
267:
257:
254:
232:
189:
186:
168:
157:
154:
141:
127:
99:Lucentis, others
37:
35:
31:
21:
6482:
6481:
6477:
6476:
6475:
6473:
6472:
6471:
6427:
6426:
6425:
6415:
6413:
6405:
6403:
6398:
6343:Midkine (NEGF2)
6221:
6004:
5903:
5672:
5610:ABT-110 (PG110)
5403:
5383:
5293:
5274:
5243:
5212:
5181:
5136:
4988:
4926:ABT-110 (PG110)
4827:
4764:
4726:
4584:
4398:
4379:
4319:
4316:(against FGF23)
4238:
4105:
4009:
3952:
3898:
3811:
3622:
3606:
3575:
3497:
3489:
3459:
3454:
3453:
3438:Clinical trials
3413:
3392:
3358:
3329:
3263:
3192:
3110:
3087:
3066:
2977:
2958:Musculoskeletal
2948:
2927:
2897:
2891:
2861:
2856:
2801:
2787:
2757:
2756:
2719:
2715:
2670:
2666:
2629:
2625:
2615:
2613:
2596:
2592:
2547:
2543:
2524:
2520:
2475:
2468:
2458:
2456:
2439:
2435:
2380:
2373:
2362:
2360:
2351:
2350:
2341:
2331:
2329:
2316:
2315:
2311:
2301:
2299:
2286:
2285:
2281:
2271:
2269:
2256:
2255:
2251:
2241:
2239:
2230:
2229:
2225:
2214:
2212:
2199:
2198:
2189:
2179:
2177:
2164:
2163:
2159:
2148:
2146:
2130:
2129:
2122:
2112:
2110:
2101:
2100:
2096:
2086:
2084:
2071:
2070:
2066:
2055:
2053:
2040:
2039:
2032:
2022:
2020:
2007:
2006:
2002:
1992:
1990:
1977:
1976:
1972:
1962:
1960:
1947:
1946:
1942:
1932:Wayback Machine
1923:
1919:
1912:
1898:
1894:
1839:
1835:
1804:(9): CD011230.
1790:
1779:
1769:
1767:
1750:
1749:
1745:
1735:
1733:
1729:
1718:
1714:
1713:
1709:
1678:(6): CD007419.
1664:
1660:
1629:(2): CD011346.
1615:
1611:
1580:(8): CD005139.
1566:
1562:
1529:(9): ED000090.
1515:
1508:
1471:
1467:
1455:
1447:
1445:
1428:
1427:
1420:
1410:
1408:
1391:
1390:
1383:
1373:
1371:
1358:
1357:
1350:
1340:
1338:
1307:
1303:
1292:
1290:
1279:"Lucentis EPAR"
1277:
1276:
1269:
1259:
1257:
1244:
1243:
1230:
1220:
1218:
1209:
1208:
1204:
1194:
1192:
1179:
1178:
1174:
1164:
1162:
1150:
1149:
1145:
1135:
1133:
1126:"Byooviz APMDS"
1124:
1123:
1116:
1106:
1104:
1091:
1090:
1083:
1072:
1070:
1057:
1056:
1047:
1037:
1035:
1022:
1021:
1012:
1002:
1000:
993:"Rimmyrah EPAR"
991:
990:
983:
973:
971:
960:"Raniviz APMDS"
958:
957:
950:
939:
937:
921:
920:
909:
899:
897:
884:
883:
872:
861:
859:
846:
845:
834:
824:
822:
809:
808:
797:
792:
772:
760:US$ 170 million
759:
721:
715:
710:
705:
681:
673:
657:endophthalmitis
646:
621:It is used for
607:
568:anti-angiogenic
536:
534:
531:(what is this?)
528:
518:
516:
506:
500:
494:
488:
482:
462:
442:
422:
402:
386:
366:
335:
326:Pharmacokinetic
320:
304:
277:
236:
204:
197:
178:
171:
28:
23:
22:
15:
12:
11:
5:
6480:
6470:
6469:
6464:
6459:
6454:
6449:
6444:
6439:
6424:
6423:
6400:
6399:
6397:
6396:
6386:
6385:
6380:
6373:Thrombopoietin
6370:
6365:
6360:
6355:
6350:
6345:
6340:
6335:
6330:
6316:
6311:
6306:
6301:
6294:Erythropoietin
6291:
6253:
6248:
6238:
6236:Adrenomedullin
6229:
6227:
6223:
6222:
6220:
6219:
6210:
6209:
6204:
6199:
6194:
6189:
6180:
6179:
6174:
6169:
6164:
6159:
6154:
6149:
6144:
6139:
6134:
6129:
6124:
6119:
6114:
6109:
6104:
6099:
6094:
6089:
6084:
6079:
6070:
6069:
6060:
6059:
6037:
6032:
6027:
6018:
6016:
6010:
6009:
6006:
6005:
6003:
6002:
5997:
5992:
5987:
5982:
5977:
5972:
5967:
5962:
5957:
5952:
5947:
5942:
5933:
5932:
5927:
5922:
5913:
5911:
5905:
5904:
5902:
5901:
5896:
5891:
5886:
5881:
5876:
5871:
5866:
5861:
5856:
5851:
5846:
5841:
5832:
5831:
5822:
5821:
5816:
5811:
5802:
5801:
5796:
5791:
5786:
5781:
5776:
5771:
5766:
5761:
5756:
5751:
5746:
5741:
5736:
5731:
5726:
5721:
5716:
5711:
5706:
5701:
5699:4'-DMA-7,8-DHF
5696:
5691:
5682:
5680:
5674:
5673:
5671:
5670:
5661:
5660:
5648:
5647:
5642:
5637:
5632:
5627:
5622:
5617:
5612:
5593:
5592:
5586:
5581:
5576:
5571:
5566:
5561:
5556:
5551:
5546:
5541:
5536:
5531:
5526:
5521:
5516:
5507:
5506:
5497:
5496:
5491:
5486:
5481:
5472:
5471:
5466:
5461:
5459:Gambogic amide
5456:
5451:
5446:
5441:
5436:
5431:
5422:
5420:
5411:
5405:
5404:
5402:
5401:
5393:
5391:
5385:
5384:
5382:
5381:
5376:
5371:
5366:
5361:
5356:
5351:
5346:
5341:
5336:
5331:
5322:
5321:
5316:
5307:
5305:
5299:
5298:
5295:
5294:
5292:
5291:
5282:
5280:
5276:
5275:
5273:
5272:
5263:
5262:
5253:
5251:
5245:
5244:
5242:
5241:
5232:
5231:
5229:Artemin (ARTN)
5222:
5220:
5214:
5213:
5211:
5210:
5201:
5200:
5191:
5189:
5183:
5182:
5180:
5179:
5170:
5169:
5164:
5155:
5153:
5144:
5138:
5137:
5135:
5134:
5129:
5124:
5115:
5114:
5109:
5104:
5099:
5094:
5089:
5084:
5079:
5074:
5069:
5064:
5059:
5054:
5049:
5044:
5039:
5030:
5029:
5007:
4998:
4996:
4990:
4989:
4987:
4986:
4977:
4976:
4964:
4963:
4958:
4953:
4948:
4943:
4938:
4933:
4928:
4916:
4915:
4910:
4905:
4900:
4891:
4890:
4885:
4880:
4875:
4870:
4865:
4860:
4855:
4850:
4841:
4839:
4833:
4832:
4829:
4828:
4826:
4825:
4820:
4811:
4810:
4772:
4770:
4766:
4765:
4763:
4762:
4756:
4747:
4746:
4736:
4734:
4728:
4727:
4725:
4724:
4718:
4713:
4708:
4703:
4698:
4693:
4688:
4683:
4674:
4673:
4668:
4663:
4658:
4653:
4644:
4643:
4638:
4633:
4628:
4623:
4618:
4613:
4603:
4601:
4592:
4586:
4585:
4583:
4582:
4577:
4572:
4567:
4562:
4557:
4552:
4543:
4542:
4537:
4532:
4527:
4522:
4517:
4512:
4507:
4502:
4497:
4492:
4487:
4482:
4477:
4472:
4467:
4462:
4457:
4452:
4447:
4438:
4437:
4428:
4427:
4422:
4412:
4410:
4404:
4403:
4400:
4399:
4397:
4396:
4387:
4385:
4381:
4380:
4378:
4377:
4372:
4338:
4329:
4327:
4321:
4320:
4318:
4317:
4307:
4306:
4301:
4296:
4291:
4257:
4248:
4246:
4240:
4239:
4237:
4236:
4227:
4226:
4221:
4212:
4211:
4206:
4201:
4196:
4191:
4186:
4124:
4115:
4113:
4107:
4106:
4104:
4103:
4098:
4093:
4088:
4083:
4041:
4032:
4030:
4021:
4015:
4014:
4011:
4010:
4008:
4007:
3981:
3976:
3971:
3962:
3960:
3954:
3953:
3951:
3950:
3945:
3940:
3931:
3930:
3908:
3906:
3900:
3899:
3897:
3896:
3891:
3886:
3881:
3876:
3867:
3866:
3861:
3856:
3851:
3846:
3841:
3832:
3831:
3821:
3819:
3813:
3812:
3810:
3809:
3804:
3799:
3794:
3789:
3784:
3779:
3774:
3769:
3764:
3755:
3754:
3749:
3744:
3739:
3734:
3729:
3724:
3719:
3714:
3709:
3704:
3699:
3694:
3689:
3680:
3679:
3674:
3669:
3664:
3659:
3654:
3649:
3644:
3639:
3629:
3627:
3614:
3608:
3607:
3605:
3604:
3599:
3594:
3585:
3583:
3577:
3576:
3574:
3573:
3567:
3557:
3556:
3551:
3546:
3537:
3536:
3534:Angiopoietin 3
3531:
3529:Angiopoietin 2
3522:
3521:
3519:Angiopoietin 4
3516:
3514:Angiopoietin 1
3507:
3505:
3499:
3498:
3488:
3487:
3480:
3473:
3465:
3456:
3455:
3452:
3451:
3450:
3449:
3446:
3435:
3429:
3423:
3422:
3419:
3418:
3415:
3414:
3412:
3411:
3406:
3400:
3398:
3394:
3393:
3391:
3390:
3385:
3379:
3377:
3370:
3364:
3363:
3360:
3359:
3357:
3356:
3350:
3348:
3341:
3335:
3334:
3331:
3330:
3328:
3327:
3322:
3317:
3312:
3307:
3302:
3297:
3292:
3287:
3282:
3277:
3271:
3269:
3265:
3264:
3262:
3261:
3256:
3251:
3246:
3241:
3240:
3239:
3234:
3229:
3224:
3213:
3211:
3204:
3198:
3197:
3194:
3193:
3191:
3190:
3185:
3180:
3175:
3170:
3165:
3160:
3155:
3150:
3145:
3140:
3135:
3126:
3120:
3118:
3112:
3111:
3109:
3108:
3103:
3097:
3095:
3089:
3088:
3086:
3085:
3080:
3074:
3072:
3068:
3067:
3065:
3064:
3059:
3054:
3049:
3044:
3039:
3034:
3029:
3024:
3019:
3014:
3009:
3004:
2998:
2996:
2989:
2983:
2982:
2979:
2978:
2976:
2975:
2969:
2967:
2960:
2954:
2953:
2950:
2949:
2947:
2946:
2941:
2935:
2933:
2929:
2928:
2926:
2925:
2920:
2914:
2912:
2905:
2899:
2898:
2890:
2889:
2882:
2875:
2867:
2858:
2857:
2855:
2854:
2849:
2844:
2839:
2834:
2829:
2824:
2819:
2813:
2811:
2803:
2802:
2786:
2785:
2778:
2771:
2763:
2755:
2754:
2713:
2684:(3): 234–239.
2664:
2623:
2590:
2561:(6): 931–939.
2555:Health Affairs
2541:
2518:
2466:
2433:
2371:
2359:. 25 July 2024
2339:
2322:MarketScreener
2309:
2279:
2262:Pharmacy Times
2249:
2223:
2187:
2157:
2120:
2094:
2064:
2030:
2000:
1970:
1940:
1934:, Lexi-Drugs.
1917:
1910:
1892:
1833:
1777:
1743:
1723:Genentech, Inc
1707:
1658:
1609:
1560:
1506:
1465:
1418:
1381:
1348:
1301:
1267:
1228:
1202:
1172:
1143:
1114:
1081:
1059:"Ximluci EPAR"
1045:
1010:
981:
948:
907:
870:
848:"Byooviz EPAR"
832:
794:
793:
791:
788:
771:
768:
740:(CHMP) of the
714:
711:
709:
706:
704:
701:
691:by inhibiting
687:that inhibits
680:
677:
672:
669:
645:
642:
606:
603:
543:
542:
525:
524:
514:
508:
507:
504:
498:
492:
486:
480:
475:
469:
468:
464:
463:
461:
460:
452:
450:
444:
443:
441:
440:
432:
430:
424:
423:
421:
420:
412:
410:
404:
403:
401:
400:
396:
394:
388:
387:
385:
384:
376:
374:
368:
367:
365:
364:
356:
354:
348:
347:
343:
342:
341:Approx. 9 days
339:
330:
329:
322:
321:
319:
318:
309:
294:
281:
265:
251:
249:
243:
242:
238:
237:
235:
234:
221:
219:
213:
212:
207:
205:administration
199:
198:
196:
195:
193:
183:
181:
173:
172:
170:
169:
151:
149:
143:
142:
135:
129:
128:
121:
111:
110:
107:
101:
100:
97:
91:
90:
86:
85:
79:
73:
72:
62:
56:
55:
50:
44:
43:
26:
9:
6:
4:
3:
2:
6479:
6468:
6465:
6463:
6460:
6458:
6455:
6453:
6450:
6448:
6445:
6443:
6440:
6438:
6435:
6434:
6432:
6422:
6412:
6411:
6408:
6394:
6391:
6388:
6387:
6384:
6381:
6378:
6374:
6371:
6369:
6366:
6364:
6361:
6359:
6356:
6354:
6351:
6349:
6346:
6344:
6341:
6339:
6336:
6334:
6331:
6328:
6324:
6320:
6317:
6315:
6312:
6310:
6307:
6305:
6302:
6299:
6295:
6292:
6289:
6285:
6281:
6277:
6273:
6269:
6265:
6261:
6257:
6254:
6252:
6249:
6246:
6242:
6239:
6237:
6234:
6231:
6230:
6228:
6224:
6218:
6215:
6212:
6211:
6208:
6205:
6203:
6200:
6198:
6195:
6193:
6190:
6188:
6185:
6182:
6181:
6178:
6175:
6173:
6170:
6168:
6165:
6163:
6160:
6158:
6155:
6153:
6150:
6148:
6145:
6143:
6140:
6138:
6135:
6133:
6130:
6128:
6125:
6123:
6120:
6118:
6115:
6113:
6110:
6108:
6105:
6103:
6100:
6098:
6095:
6093:
6090:
6088:
6085:
6083:
6080:
6078:
6075:
6072:
6071:
6068:
6067:Cyclotraxin B
6065:
6062:
6061:
6057:
6053:
6049:
6045:
6041:
6038:
6036:
6033:
6031:
6028:
6026:
6023:
6020:
6019:
6017:
6015:
6011:
6001:
5998:
5996:
5993:
5991:
5988:
5986:
5983:
5981:
5980:Larotrectinib
5978:
5976:
5973:
5971:
5968:
5966:
5963:
5961:
5958:
5956:
5953:
5951:
5948:
5946:
5943:
5941:
5938:
5935:
5934:
5931:
5928:
5926:
5923:
5921:
5918:
5915:
5914:
5912:
5910:
5906:
5900:
5897:
5895:
5892:
5890:
5887:
5885:
5882:
5880:
5879:Larotrectinib
5877:
5875:
5872:
5870:
5867:
5865:
5862:
5860:
5857:
5855:
5852:
5850:
5847:
5845:
5842:
5840:
5837:
5834:
5833:
5830:
5827:
5824:
5823:
5820:
5817:
5815:
5814:Cyclotraxin B
5812:
5810:
5807:
5804:
5803:
5800:
5797:
5795:
5792:
5790:
5787:
5785:
5782:
5780:
5777:
5775:
5772:
5770:
5767:
5765:
5762:
5760:
5757:
5755:
5752:
5750:
5747:
5745:
5742:
5740:
5737:
5735:
5732:
5730:
5727:
5725:
5724:Amitriptyline
5722:
5720:
5717:
5715:
5712:
5710:
5707:
5705:
5702:
5700:
5697:
5695:
5692:
5690:
5687:
5684:
5683:
5681:
5679:
5675:
5669:
5666:
5663:
5662:
5659:
5656:
5653:
5650:
5649:
5646:
5643:
5641:
5638:
5636:
5633:
5631:
5628:
5626:
5623:
5621:
5618:
5616:
5613:
5611:
5608:
5604:
5601:
5600:Against TrkA:
5598:
5595:
5594:
5590:
5587:
5585:
5582:
5580:
5577:
5575:
5572:
5570:
5567:
5565:
5562:
5560:
5557:
5555:
5554:Larotrectinib
5552:
5550:
5547:
5545:
5542:
5540:
5537:
5535:
5532:
5530:
5527:
5525:
5522:
5520:
5517:
5515:
5512:
5509:
5508:
5505:
5502:
5499:
5498:
5495:
5492:
5490:
5487:
5485:
5484:Dexamethasone
5482:
5480:
5477:
5474:
5473:
5470:
5467:
5465:
5462:
5460:
5457:
5455:
5452:
5450:
5447:
5445:
5442:
5440:
5437:
5435:
5432:
5430:
5429:Amitriptyline
5427:
5424:
5423:
5421:
5419:
5415:
5412:
5410:
5406:
5399:
5395:
5394:
5392:
5390:
5386:
5380:
5377:
5375:
5372:
5370:
5367:
5365:
5362:
5360:
5357:
5355:
5352:
5350:
5347:
5345:
5342:
5340:
5337:
5335:
5332:
5330:
5327:
5324:
5323:
5320:
5317:
5315:
5312:
5309:
5308:
5306:
5304:
5300:
5290:
5287:
5284:
5283:
5281:
5277:
5271:
5268:
5265:
5264:
5261:
5258:
5255:
5254:
5252:
5250:
5246:
5240:
5237:
5234:
5233:
5230:
5227:
5224:
5223:
5221:
5219:
5215:
5209:
5206:
5203:
5202:
5199:
5196:
5193:
5192:
5190:
5188:
5184:
5178:
5175:
5172:
5171:
5168:
5165:
5163:
5160:
5157:
5156:
5154:
5152:
5148:
5145:
5143:
5139:
5133:
5130:
5128:
5125:
5123:
5120:
5117:
5116:
5113:
5110:
5108:
5105:
5103:
5100:
5098:
5095:
5093:
5090:
5088:
5085:
5083:
5080:
5078:
5075:
5073:
5070:
5068:
5065:
5063:
5060:
5058:
5055:
5053:
5050:
5048:
5045:
5043:
5040:
5038:
5035:
5032:
5031:
5027:
5023:
5019:
5015:
5011:
5008:
5006:
5003:
5000:
4999:
4997:
4995:
4991:
4985:
4982:
4979:
4978:
4975:
4972:
4969:
4966:
4965:
4962:
4959:
4957:
4954:
4952:
4949:
4947:
4944:
4942:
4939:
4937:
4934:
4932:
4929:
4927:
4924:
4921:
4918:
4917:
4914:
4911:
4909:
4906:
4904:
4903:Dexamethasone
4901:
4899:
4896:
4893:
4892:
4889:
4886:
4884:
4881:
4879:
4876:
4874:
4871:
4869:
4866:
4864:
4861:
4859:
4856:
4854:
4851:
4849:
4846:
4843:
4842:
4840:
4838:
4834:
4824:
4821:
4819:
4816:
4813:
4812:
4808:
4804:
4800:
4796:
4792:
4788:
4784:
4780:
4777:
4774:
4773:
4771:
4767:
4760:
4757:
4755:
4752:
4749:
4748:
4745:
4741:
4738:
4737:
4735:
4733:
4729:
4722:
4719:
4717:
4714:
4712:
4709:
4707:
4704:
4702:
4699:
4697:
4694:
4692:
4689:
4687:
4684:
4682:
4679:
4676:
4675:
4672:
4669:
4667:
4664:
4662:
4659:
4657:
4654:
4652:
4649:
4646:
4645:
4642:
4639:
4637:
4634:
4632:
4629:
4627:
4624:
4622:
4619:
4617:
4614:
4612:
4611:des(1-3)IGF-1
4608:
4605:
4604:
4602:
4600:
4596:
4593:
4591:
4587:
4581:
4578:
4576:
4575:Telisotuzumab
4573:
4571:
4568:
4566:
4563:
4561:
4558:
4556:
4553:
4551:
4548:
4545:
4544:
4541:
4538:
4536:
4533:
4531:
4528:
4526:
4523:
4521:
4518:
4516:
4513:
4511:
4508:
4506:
4503:
4501:
4498:
4496:
4493:
4491:
4488:
4486:
4483:
4481:
4478:
4476:
4473:
4471:
4468:
4466:
4463:
4461:
4458:
4456:
4453:
4451:
4448:
4446:
4443:
4440:
4439:
4436:
4433:
4432:Potentiators:
4430:
4429:
4426:
4423:
4421:
4417:
4414:
4413:
4411:
4409:
4405:
4395:
4392:
4389:
4388:
4386:
4382:
4376:
4373:
4370:
4366:
4362:
4358:
4354:
4350:
4346:
4342:
4339:
4337:
4334:
4331:
4330:
4328:
4326:
4322:
4315:
4312:
4309:
4308:
4305:
4302:
4300:
4297:
4295:
4294:Selpercatinib
4292:
4289:
4285:
4281:
4277:
4273:
4269:
4265:
4261:
4258:
4256:
4253:
4250:
4249:
4247:
4245:
4241:
4235:
4232:
4229:
4228:
4225:
4222:
4220:
4217:
4214:
4213:
4210:
4207:
4205:
4202:
4200:
4199:Selpercatinib
4197:
4195:
4192:
4190:
4187:
4184:
4180:
4176:
4172:
4168:
4164:
4160:
4156:
4152:
4148:
4144:
4140:
4136:
4132:
4128:
4125:
4123:
4120:
4117:
4116:
4114:
4112:
4108:
4102:
4099:
4097:
4094:
4092:
4091:Selpercatinib
4089:
4087:
4084:
4081:
4077:
4073:
4069:
4065:
4061:
4057:
4053:
4049:
4045:
4042:
4040:
4037:
4034:
4033:
4031:
4029:
4025:
4022:
4020:
4016:
4005:
4001:
3997:
3993:
3989:
3985:
3982:
3980:
3977:
3975:
3972:
3970:
3967:
3964:
3963:
3961:
3959:
3955:
3949:
3946:
3944:
3941:
3939:
3936:
3933:
3932:
3928:
3924:
3920:
3916:
3913:
3910:
3909:
3907:
3905:
3901:
3895:
3892:
3890:
3887:
3885:
3882:
3880:
3877:
3875:
3872:
3869:
3868:
3865:
3862:
3860:
3857:
3855:
3852:
3850:
3847:
3845:
3842:
3840:
3837:
3834:
3833:
3830:
3826:
3823:
3822:
3820:
3818:
3814:
3808:
3805:
3803:
3800:
3798:
3795:
3793:
3790:
3788:
3785:
3783:
3780:
3778:
3775:
3773:
3770:
3768:
3767:Depatuxizumab
3765:
3763:
3760:
3757:
3756:
3753:
3750:
3748:
3745:
3743:
3740:
3738:
3735:
3733:
3730:
3728:
3725:
3723:
3720:
3718:
3715:
3713:
3710:
3708:
3705:
3703:
3700:
3698:
3695:
3693:
3690:
3688:
3685:
3682:
3681:
3678:
3675:
3673:
3670:
3668:
3665:
3663:
3660:
3658:
3655:
3653:
3650:
3648:
3645:
3643:
3640:
3638:
3634:
3631:
3630:
3628:
3626:
3618:
3615:
3613:
3609:
3603:
3600:
3598:
3595:
3593:
3590:
3587:
3586:
3584:
3582:
3578:
3571:
3568:
3565:
3562:
3559:
3558:
3555:
3552:
3550:
3547:
3545:
3542:
3539:
3538:
3535:
3532:
3530:
3527:
3524:
3523:
3520:
3517:
3515:
3512:
3509:
3508:
3506:
3504:
3500:
3496:
3493:
3486:
3481:
3479:
3474:
3472:
3467:
3466:
3463:
3447:
3445:
3442:
3441:
3439:
3436:
3433:
3430:
3428:
3425:
3424:
3420:
3410:
3409:Landogrozumab
3407:
3405:
3402:
3401:
3399:
3395:
3389:
3386:
3384:
3381:
3380:
3378:
3374:
3371:
3369:
3368:Growth factor
3365:
3355:
3352:
3351:
3349:
3345:
3342:
3340:
3336:
3326:
3323:
3321:
3318:
3316:
3313:
3311:
3308:
3306:
3303:
3301:
3298:
3296:
3293:
3291:
3288:
3286:
3283:
3281:
3278:
3276:
3273:
3272:
3270:
3266:
3260:
3257:
3255:
3252:
3250:
3247:
3245:
3242:
3238:
3235:
3233:
3230:
3228:
3225:
3223:
3220:
3219:
3218:
3215:
3214:
3212:
3208:
3205:
3203:
3199:
3189:
3186:
3184:
3181:
3179:
3178:Ralpancizumab
3176:
3174:
3171:
3169:
3166:
3164:
3161:
3159:
3156:
3154:
3151:
3149:
3146:
3144:
3141:
3139:
3136:
3134:
3130:
3127:
3125:
3122:
3121:
3119:
3117:
3113:
3107:
3104:
3102:
3099:
3098:
3096:
3094:
3090:
3084:
3081:
3079:
3076:
3075:
3073:
3069:
3063:
3060:
3058:
3055:
3053:
3050:
3048:
3045:
3043:
3040:
3038:
3035:
3033:
3030:
3028:
3025:
3023:
3020:
3018:
3015:
3013:
3012:Ascrinvacumab
3010:
3008:
3005:
3003:
3000:
2999:
2997:
2993:
2990:
2988:
2984:
2974:
2971:
2970:
2968:
2964:
2961:
2959:
2955:
2945:
2942:
2940:
2937:
2936:
2934:
2930:
2924:
2921:
2919:
2916:
2915:
2913:
2909:
2906:
2904:
2900:
2895:
2888:
2883:
2881:
2876:
2874:
2869:
2868:
2865:
2853:
2850:
2848:
2845:
2843:
2840:
2838:
2835:
2833:
2830:
2828:
2825:
2823:
2820:
2818:
2815:
2814:
2812:
2809:
2804:
2799:
2795:
2791:
2784:
2779:
2777:
2772:
2770:
2765:
2764:
2761:
2750:
2746:
2741:
2736:
2732:
2728:
2724:
2717:
2709:
2705:
2701:
2697:
2692:
2687:
2683:
2679:
2675:
2668:
2660:
2656:
2651:
2646:
2642:
2638:
2634:
2627:
2611:
2607:
2606:
2601:
2594:
2586:
2582:
2577:
2572:
2568:
2564:
2560:
2556:
2552:
2545:
2537:
2533:
2529:
2522:
2514:
2510:
2505:
2500:
2496:
2492:
2488:
2484:
2480:
2473:
2471:
2454:
2450:
2449:
2444:
2437:
2429:
2425:
2420:
2415:
2410:
2405:
2401:
2397:
2394:(8): e42701.
2393:
2389:
2385:
2378:
2376:
2358:
2354:
2348:
2346:
2344:
2327:
2323:
2319:
2313:
2297:
2293:
2289:
2283:
2267:
2263:
2259:
2253:
2237:
2233:
2232:"Rimmyrah PI"
2227:
2210:
2206:
2202:
2196:
2194:
2192:
2175:
2171:
2167:
2161:
2144:
2140:
2138:
2133:
2127:
2125:
2108:
2104:
2098:
2082:
2078:
2074:
2068:
2051:
2047:
2043:
2037:
2035:
2018:
2014:
2010:
2004:
1988:
1984:
1980:
1974:
1958:
1954:
1950:
1949:"ranibizumab"
1944:
1937:
1933:
1929:
1926:
1921:
1913:
1907:
1903:
1902:Austria-Codex
1896:
1888:
1884:
1879:
1874:
1869:
1864:
1860:
1856:
1853:(8): e42701.
1852:
1848:
1844:
1837:
1829:
1825:
1820:
1815:
1811:
1807:
1803:
1799:
1795:
1788:
1786:
1784:
1782:
1765:
1761:
1759:
1753:
1747:
1728:
1724:
1717:
1711:
1703:
1699:
1694:
1689:
1685:
1681:
1677:
1673:
1669:
1662:
1654:
1650:
1645:
1640:
1636:
1632:
1628:
1624:
1620:
1613:
1605:
1601:
1596:
1591:
1587:
1583:
1579:
1575:
1571:
1564:
1556:
1552:
1547:
1542:
1537:
1532:
1528:
1524:
1520:
1513:
1511:
1502:
1498:
1493:
1488:
1484:
1480:
1476:
1469:
1462:
1461:public domain
1443:
1439:
1437:
1431:
1425:
1423:
1406:
1402:
1400:
1394:
1388:
1386:
1369:
1365:
1361:
1355:
1353:
1336:
1332:
1328:
1324:
1320:
1316:
1312:
1305:
1288:
1284:
1280:
1274:
1272:
1255:
1251:
1247:
1241:
1239:
1237:
1235:
1233:
1216:
1212:
1206:
1190:
1186:
1185:Health Canada
1182:
1176:
1161:
1157:
1153:
1147:
1131:
1127:
1121:
1119:
1102:
1098:
1094:
1088:
1086:
1068:
1064:
1060:
1054:
1052:
1050:
1033:
1029:
1025:
1019:
1017:
1015:
998:
994:
988:
986:
969:
965:
961:
955:
953:
935:
931:
929:
924:
918:
916:
914:
912:
895:
891:
887:
881:
879:
877:
875:
857:
853:
849:
843:
841:
839:
837:
820:
816:
812:
806:
804:
802:
800:
795:
787:
783:
779:
777:
767:
763:
756:
752:
748:
745:
743:
739:
734:
732:
731:Lupin Limited
727:
724:
720:
700:
698:
694:
690:
686:
676:
668:
666:
662:
658:
653:
650:
641:
638:
636:
632:
628:
624:
619:
615:
612:
602:
600:
596:
591:
589:
585:
581:
580:macular edema
577:
573:
569:
565:
561:
557:
553:
549:
539:
532:
526:
515:
513:
509:
476:
474:
470:
465:
458:
457:ChEMBL1201825
454:
453:
451:
449:
445:
438:
434:
433:
431:
429:
425:
418:
414:
413:
411:
409:
405:
398:
397:
395:
393:
389:
382:
378:
377:
375:
373:
369:
362:
358:
357:
355:
353:
349:
344:
340:
338:
331:
327:
323:
317: Rx-only
310:
307:
295:
292:
282:
275:
266:
263:
253:
252:
250:
248:
244:
239:
231:
226:
223:
222:
220:
218:
214:
211:
208:
206:
200:
194:
185:
184:
182:
180:
174:
167:
162:
153:
152:
150:
148:
144:
140:
136:
134:
130:
126:
122:
120:
116:
112:
108:
106:
102:
98:
96:
92:
89:Clinical data
87:
83:
80:
78:
74:
70:
66:
63:
61:
57:
54:
51:
49:
45:
42:
38:
30:
19:
6467:Orphan drugs
6393:Cerebrolysin
6389:
6363:Pleiotrophin
6319:Interleukins
6232:
6213:
6206:
6183:
6102:Fruquintinib
6092:Cabozantinib
6073:
6063:
6021:
5985:Lestaurtinib
5936:
5916:
5884:Lestaurtinib
5835:
5825:
5806:Antagonists:
5805:
5739:Deoxygedunin
5694:3,7,8,2'-THF
5685:
5664:
5655:Against NGF:
5654:
5651:
5607:Against NGF:
5606:
5599:
5596:
5559:Lestaurtinib
5510:
5500:
5494:Testosterone
5476:Antagonists:
5475:
5425:
5325:
5310:
5285:
5266:
5256:
5235:
5225:
5204:
5194:
5173:
5158:
5118:
5033:
5001:
4980:
4971:Against NGF:
4970:
4967:
4923:Against NGF:
4922:
4919:
4913:Testosterone
4895:Antagonists:
4894:
4844:
4814:
4775:
4750:
4739:
4716:Teprotumumab
4677:
4647:
4606:
4555:Ficlatuzumab
4550:Emibetuzumab
4546:
4500:JNJ-38877605
4470:Cabozantinib
4441:
4431:
4420:Fosgonimeton
4415:
4390:
4332:
4310:
4251:
4234:Infigratinib
4230:
4215:
4118:
4035:
3969:Betacellulin
3965:
3948:Seribantumab
3934:
3911:
3870:
3835:
3829:Unknown/none
3828:
3824:
3758:
3683:
3642:Betacellulin
3637:Amphiregulin
3632:
3624:(ErbB1/HER1)
3588:
3560:
3540:
3526:Antagonists:
3525:
3510:
3503:Angiopoietin
3404:Domagrozumab
3353:
3295:Galcanezumab
3290:Fremanezumab
3275:Bapineuzumab
3232:Gantenerumab
3173:Idarucizumab
3163:Etaracizumab
3148:Caplacizumab
3143:Brolucizumab
3132:
2846:
2832:Brolucizumab
2730:
2726:
2716:
2681:
2677:
2667:
2640:
2636:
2626:
2614:. Retrieved
2603:
2593:
2558:
2554:
2544:
2536:the original
2531:
2521:
2486:
2482:
2459:10 September
2457:. Retrieved
2446:
2436:
2391:
2387:
2361:. Retrieved
2356:
2330:. Retrieved
2321:
2312:
2300:. Retrieved
2291:
2282:
2270:. Retrieved
2261:
2252:
2240:. Retrieved
2235:
2226:
2213:. Retrieved
2204:
2178:. Retrieved
2169:
2160:
2149:18 September
2147:. Retrieved
2135:
2111:. Retrieved
2097:
2085:. Retrieved
2076:
2067:
2054:. Retrieved
2045:
2021:. Retrieved
2012:
2003:
1991:. Retrieved
1982:
1973:
1961:. Retrieved
1952:
1943:
1936:Ranibizumab.
1935:
1920:
1901:
1895:
1850:
1846:
1836:
1801:
1797:
1768:. Retrieved
1755:
1746:
1734:. Retrieved
1722:
1710:
1675:
1671:
1661:
1626:
1622:
1612:
1577:
1573:
1563:
1526:
1522:
1485:(2): 39–49.
1482:
1478:
1468:
1448:20 September
1446:. Retrieved
1433:
1409:. Retrieved
1396:
1372:. Retrieved
1368:the original
1363:
1339:. Retrieved
1314:
1304:
1291:. Retrieved
1282:
1260:20 September
1258:. Retrieved
1249:
1219:. Retrieved
1214:
1205:
1195:29 September
1193:. Retrieved
1184:
1175:
1163:. Retrieved
1155:
1146:
1134:. Retrieved
1129:
1107:20 September
1105:. Retrieved
1096:
1071:. Retrieved
1062:
1036:. Retrieved
1027:
1001:. Retrieved
996:
972:. Retrieved
963:
938:. Retrieved
926:
898:. Retrieved
889:
860:. Retrieved
851:
823:. Retrieved
814:
784:
780:
773:
764:
757:
753:
749:
746:
735:
728:
725:
722:
708:Legal status
689:angiogenesis
682:
679:Pharmacology
674:
671:Interactions
654:
651:
647:
644:Side effects
639:
620:
616:
608:
605:Medical uses
592:
551:
547:
546:
535:
529:
334:Elimination
247:Legal status
241:Legal status
147:License data
53:Fab fragment
29:
6353:Oncomodulin
6217:Aflibercept
6207:Ranibizumab
6202:Ramucirumab
6192:Bevacizumab
6184:Antibodies:
6142:Regorafenib
6082:Altiratinib
5995:ONO-5390556
5965:Entrectinib
5940:Altiratinib
5894:ONO-5390556
5864:Entrectinib
5839:Altiratinib
5625:Frunevetmab
5597:Antibodies:
5574:ONO-5390556
5539:Entrectinib
5514:Altiratinib
5469:Tavilermide
5364:Quizartinib
5303:SCF (c-Kit)
5127:Ramucirumab
5119:Antibodies:
5092:Quizartinib
5042:Avapritinib
5005:Becaplermin
4941:Frunevetmab
4920:Antibodies:
4823:Trofinetide
4754:Dusigitumab
4751:Antibodies:
4706:Robatumumab
4696:Figitumumab
4691:Dalotuzumab
4686:Cixutumumab
4678:Antibodies:
4570:Rilotumumab
4565:Onartuzumab
4560:Flanvotumab
4547:Antibodies:
4515:PF-04217903
4445:Altiratinib
4408:HGF (c-Met)
4311:Antibodies:
4216:Antibodies:
3938:Duligotumab
3935:Antibodies:
3849:Trastuzumab
3839:Ertumaxomab
3836:Antibodies:
3807:Zalutumumab
3802:Panitumumab
3797:Nimotuzumab
3792:Necitumumab
3782:Imgatuzumab
3759:Antibodies:
3742:Osimertinib
3707:Dacomitinib
3602:Dapiclermin
3561:Antibodies:
3544:Altiratinib
3434:from market
3388:Trevogrumab
3354:Ranibizumab
3320:Solanezumab
3315:Semorinemab
3310:Refanezumab
3285:Eptinezumab
3188:Vanucizumab
3183:Tadocizumab
3138:Bococizumab
3133:Ranibizumab
3129:Bevacizumab
3106:Volociximab
3057:Ramucirumab
3017:Bentracimab
2987:Circulatory
2944:Romosozumab
2894:Monoclonals
2852:Verteporfin
2847:Ranibizumab
2827:Bevacizumab
2817:Aflibercept
2616:25 February
2242:7 September
2023:24 November
1925:Ranibizumab
1293:9 September
1038:19 December
1003:7 September
862:9 September
776:bevacizumab
719:Biosimilars
713:Biosimilars
697:Bevacizumab
631:aflibercept
627:bevacizumab
566:. It is an
564:bevacizumab
548:Ranibizumab
523: g·mol
361:347396-82-1
346:Identifiers
166:Ranibizumab
133:MedlinePlus
105:Biosimilars
95:Trade names
34:Ranibizumab
6431:Categories
6172:Vandetanib
6137:Rebastinib
6132:Pegaptanib
6122:Nintedanib
6112:Lenvatinib
6077:Agerafenib
6030:Ripretinib
5955:CH-7057288
5854:CH-7057288
5719:7,8,3'-THF
5714:7,8,2'-THF
5640:Ranevetmab
5630:Fulranumab
5584:Rebastinib
5529:CH-7057288
5444:Cenegermin
5329:Agerafenib
5289:Agerafenib
5270:Vandetanib
5239:Vandetanib
5208:Vandetanib
5177:Vandetanib
5122:Olaratumab
5097:Ripretinib
5077:Nintedanib
5062:Lenvatinib
5052:Crenolanib
5037:Agerafenib
4956:Ranevetmab
4946:Fulranumab
4863:Cenegermin
4837:LNGF (p75)
4759:Xentuzumab
4721:Xentuzumab
4666:NVP-AEW541
4661:NVP-ADW742
4656:Linsitinib
4651:BMS-754807
4636:Mecasermin
4535:Tivantinib
4525:PHA-665752
4520:PF-2341066
4490:Golvatinib
4480:Crizotinib
4475:Capmatinib
4465:BMS-777607
4460:Amuvatinib
4336:Ersofermin
4299:Sprifermin
4255:Ersofermin
4204:Sprifermin
4194:Repifermin
4189:Palifermin
4122:Ersofermin
4101:Velafermin
4086:Repifermin
4039:Ersofermin
3958:ErbB4/HER4
3943:Patritumab
3904:ErbB3/HER3
3884:Mubritinib
3844:Pertuzumab
3817:ErbB2/HER2
3747:Vandetanib
3702:Canertinib
3697:Brigatinib
3692:Agerafenib
3672:Nepidermin
3667:Murodermin
3657:Epiregulin
3612:EGF (ErbB)
3570:Nesvacumab
3564:Evinacumab
3554:Rebastinib
3495:modulators
3383:Bimagrumab
3300:Ozanezumab
3280:Crenezumab
3259:Opicinumab
3254:Fulranumab
3222:Aducanumab
3202:Neurologic
3158:Emicizumab
3153:Demcizumab
3047:Nesvacumab
3042:Inclacumab
3032:Evolocumab
3027:Evinacumab
3022:Enoticumab
3007:Alirocumab
3002:Abelacimab
2973:Stamulumab
2939:Blosozumab
2842:Pegaptanib
2822:Anecortave
2332:22 January
2302:22 January
2272:22 January
2215:5 December
1374:28 October
1165:22 October
900:21 January
790:References
729:In India,
717:See also:
558:fragment (
512:Molar mass
417:ZL1R02VT79
392:ChemSpider
352:CAS Number
280:Schedule D
6197:Icrucumab
6177:WHI-P 154
6167:Tivozanib
6162:Toceranib
6157:Sunitinib
6152:Sorafenib
6147:Semaxanib
6127:Pazopanib
6117:Motesanib
6107:Lapatinib
6097:Cediranib
6035:Telbermin
6022:Agonists:
5970:GZ-389988
5950:CE-245677
5917:Agonists:
5869:GZ-389988
5849:CE-245677
5749:Diosmetin
5686:Agonists:
5652:Aptamers:
5645:Tanezumab
5620:Fasinumab
5564:Milciclib
5544:GZ-389988
5524:CE-245677
5426:Agonists:
5379:Toceranib
5374:Sunitinib
5369:Sorafenib
5359:Pazopanib
5354:Nilotinib
5349:Masitinib
5339:Dasatinib
5311:Agonists:
5257:Agonists:
5226:Agonists:
5195:Agonists:
5167:Liatermin
5159:Agonists:
5142:RET (GFL)
5132:Tovetumab
5112:Toceranib
5107:Sorafenib
5102:Sunitinib
5087:Radotinib
5082:Pazopanib
5072:Motesanib
5067:Masitinib
5002:Agonists:
4968:Aptamers:
4961:Tanezumab
4936:Fasinumab
4845:Agonists:
4701:Ganitumab
4621:IGF-1 LR3
4540:Volitinib
4495:INCB28060
4485:Foretinib
4391:Agonists:
4375:Trafermin
4333:Agonists:
4314:Burosumab
4304:Trafermin
4252:Agonists:
4219:Aprutumab
4209:Trafermin
4171:10 (KGF2)
4119:Agonists:
4096:Trafermin
4076:10 (KGF2)
4036:Agonists:
3966:Agonists:
3912:Agonists:
3894:Tucatinib
3889:Neratinib
3879:Lapatinib
3787:Matuzumab
3777:Futuximab
3762:Cetuximab
3752:WHI-P 154
3737:Neratinib
3732:Lapatinib
3722:Grandinin
3717:Gefitinib
3712:Erlotinib
3589:Agonists:
3549:CE-245677
3511:Agonists:
3444:Phase III
3432:Withdrawn
3397:Humanized
3347:Humanized
3325:Tanezumab
3305:Ponezumab
3268:Humanized
3249:Fasinumab
3237:Lecanemab
3227:Donanemab
3168:Faricimab
3116:Humanized
3101:Abciximab
3083:Imciromab
3078:Biciromab
3062:Rinucumab
3052:Orticumab
3037:Icrucumab
2932:Humanized
2923:Denosumab
2918:Burosumab
2837:Faricimab
2792:: ocular
1364:Genentech
1341:1 October
940:6 October
770:Economics
665:cataracts
611:indicated
595:Genentech
336:half-life
203:Routes of
177:Pregnancy
125:Monograph
119:Drugs.com
65:Humanized
6421:Medicine
6379:instead)
6368:Renalase
6329:instead)
6300:instead)
6247:instead)
6087:Axitinib
6056:D (FIGF)
6000:PLX-7486
5990:ONO-4474
5945:AZD-6918
5899:PLX-7486
5889:ONO-4474
5844:AZD-6918
5826:Ligands:
5744:Deprenyl
5704:7,3'-DHF
5635:MEDI-578
5615:ASP-6294
5579:PLX-7486
5569:ONO-4474
5519:AZD-6918
5479:ALE-0540
5400:instead.
5344:Imatinib
5334:Axitinib
5314:Ancestim
5279:Unsorted
5057:Imatinib
5047:Axitinib
4951:MEDI-578
4931:ASP-6294
4898:ALE-0540
4740:Agonists
4681:AVE-1642
4607:Agonists
4530:SU-11274
4416:Agonists
4394:FGF15/19
4384:Unsorted
4349:2 (bFGF)
4268:2 (bFGF)
4135:2 (bFGF)
4052:2 (bFGF)
3874:Afatinib
3825:Agonists
3727:Icotinib
3687:Afatinib
3633:Agonists
3244:Erenumab
3093:Chimeric
2796:agents (
2749:23870813
2708:23979022
2700:24635444
2659:20885427
2610:Archived
2585:24889941
2532:Medscape
2513:21526923
2453:Archived
2428:22880086
2388:PLOS ONE
2326:Archived
2296:Archived
2266:Archived
2209:Archived
2174:Archived
2143:Archived
2113:2 August
2107:Archived
2081:Archived
2050:Archived
2017:Archived
1987:Archived
1963:24 March
1957:Archived
1953:medscape
1928:Archived
1887:22880086
1847:PLOS ONE
1828:25220133
1770:2 August
1764:Archived
1727:Archived
1702:38275741
1693:10294542
1653:26857947
1604:25170575
1555:25228121
1546:10845851
1501:26060829
1442:Archived
1411:2 August
1405:Archived
1335:Archived
1331:21417187
1287:Archived
1254:Archived
1250:DailyMed
1189:Archived
1101:Archived
1067:Archived
1032:Archived
1028:DailyMed
968:Archived
934:Archived
894:Archived
890:DailyMed
856:Archived
825:2 August
819:Archived
815:DailyMed
599:Novartis
552:Lucentis
538:(verify)
372:DrugBank
217:ATC code
179:category
161:DailyMed
84:(VEGF-A)
18:Lucentis
6256:Ephrins
5960:DS-6051
5859:DS-6051
5764:LM22A-4
5754:DMAQ-B1
5709:7,8-DHF
5689:3,7-DHF
5658:RBM-004
5603:GBR-900
5534:DS-6051
5504:VM-902A
4974:RBM-004
4671:OSl-906
4631:Insulin
4510:MK-2461
4455:AMG-458
3592:Axokine
2576:4137040
2504:3157322
2419:3411814
2396:Bibcode
2363:27 July
2180:3 March
2087:3 March
2056:26 June
1993:3 March
1878:3411814
1855:Bibcode
1819:4262120
1736:23 July
1644:5030844
1595:4270425
1492:4458325
1221:23 July
1136:7 March
1073:3 March
974:7 March
582:due to
473:Formula
381:DB01270
308:Rx-only
305:WARNING
276: /
272::
233:)
227: (
225:S01LA04
192: D
163::
139:a607044
6407:Portal
6226:Others
5920:BNN-20
5809:ANA-12
5734:BNN-20
5454:DHEA-S
5439:BNN-27
5434:BNN-20
4873:DHEA-S
4858:BNN-27
4853:BNN-20
4769:Others
3974:Epigen
3652:Epigen
3427:WHO-EM
2810:agents
2747:
2727:Lancet
2706:
2698:
2657:
2583:
2573:
2511:
2501:
2426:
2416:
2292:Sandoz
1908:
1885:
1875:
1826:
1816:
1700:
1690:
1651:
1641:
1602:
1592:
1553:
1543:
1499:
1489:
1329:
578:, and
448:ChEMBL
437:D05697
302:
289:
278:
274:℞-only
260:
159:
77:Target
67:(from
60:Source
6375:(see
6325:(see
6296:(see
6243:(see
5975:K252a
5874:K252a
5549:K252a
5489:FX007
5249:GFRα4
5218:GFRα3
5187:GFRα2
5151:GFRα1
4779:IGFBP
4732:IGF-2
4711:R1507
4599:IGF-1
4505:K252a
4325:FGFR4
4244:FGFR3
4111:FGFR2
4028:FGFR1
3376:Human
3210:Human
3071:Mouse
2995:Human
2966:Human
2911:Human
2704:S2CID
2139:(EMA)
1760:(FDA)
1756:U.S.
1730:(PDF)
1719:(PDF)
1438:(FDA)
1434:U.S.
1401:(FDA)
1397:U.S.
930:(EMA)
69:mouse
6377:here
6327:here
6298:here
6245:here
6040:VEGF
6014:VEGF
5930:NT-3
5925:DHEA
5909:TrkC
5829:DHEA
5799:TDP6
5779:NT-4
5774:NT-3
5759:HIOC
5729:BDNF
5678:TrkB
5449:DHEA
5418:TrkA
5398:here
5396:See
5389:TGFβ
4994:PDGF
4888:NT-4
4883:NT-3
4868:DHEA
4848:BDNF
3597:CNTF
3581:CNTF
2903:Bone
2806:Anti
2798:S01L
2745:PMID
2696:PMID
2655:PMID
2618:2017
2581:PMID
2509:PMID
2461:2017
2424:PMID
2365:2024
2334:2024
2304:2024
2274:2024
2244:2024
2217:2023
2182:2023
2151:2022
2115:2022
2089:2023
2058:2022
2025:2021
1995:2023
1965:2015
1906:ISBN
1883:PMID
1824:PMID
1772:2022
1738:2024
1698:PMID
1676:2023
1649:PMID
1627:2016
1600:PMID
1551:PMID
1497:PMID
1450:2021
1413:2022
1376:2012
1343:2021
1327:PMID
1295:2021
1262:2021
1223:2024
1197:2022
1167:2023
1138:2024
1109:2021
1075:2023
1040:2021
1005:2024
976:2024
942:2022
902:2023
864:2021
827:2022
629:and
487:3282
481:2158
428:KEGG
408:UNII
399:none
328:data
115:AHFS
48:Type
5794:R13
5464:NGF
5409:Trk
4878:NGF
4590:IGF
4450:AM7
4341:FGF
4260:FGF
4161:),
4159:KGF
4127:FGF
4044:FGF
4019:FGF
3621:EGF
2735:doi
2731:382
2686:doi
2645:doi
2637:Eye
2571:PMC
2563:doi
2499:PMC
2491:doi
2487:364
2414:PMC
2404:doi
1873:PMC
1863:doi
1814:PMC
1806:doi
1688:PMC
1680:doi
1639:PMC
1631:doi
1590:PMC
1582:doi
1541:PMC
1531:doi
1487:PMC
1319:doi
1160:FDA
586:or
560:Fab
521:.97
519:379
499:681
493:562
291:POM
230:WHO
6433::
6288:B3
6286:,
6284:B2
6282:,
6280:B1
6278:,
6276:A5
6274:,
6272:A4
6270:,
6268:A3
6266:,
6264:A2
6262:,
6260:A1
6054:,
6050:,
6046:,
5789:R7
5605:;
5024:,
5020:,
5016:,
4805:,
4801:,
4797:,
4793:,
4789:,
4785:,
4742::
4609::
4418::
4369:19
4367:,
4363:,
4359:,
4355:,
4351:,
4347:,
4288:23
4286:,
4284:18
4282:,
4278:,
4274:,
4270:,
4266:,
4183:22
4181:,
4179:18
4177:,
4175:17
4173:,
4169:,
4165:,
4153:,
4149:,
4145:,
4141:,
4137:,
4133:,
4080:20
4078:,
4074:,
4070:,
4066:,
4062:,
4058:,
4054:,
4050:,
4002:,
3998:,
3994:,
3990:,
3925:,
3921:,
3827::
3635::
3440::
2743:.
2729:.
2725:.
2702:.
2694:.
2682:39
2680:.
2676:.
2653:.
2641:24
2639:.
2635:.
2608:.
2602:.
2579:.
2569:.
2559:33
2557:.
2553:.
2530:.
2507:.
2497:.
2485:.
2481:.
2469:^
2451:.
2445:.
2422:.
2412:.
2402:.
2390:.
2386:.
2374:^
2355:.
2342:^
2320:.
2290:.
2260:.
2234:.
2203:.
2190:^
2172:.
2168:.
2134:.
2123:^
2079:.
2075:.
2044:.
2033:^
2015:.
2011:.
1985:.
1981:.
1955:.
1951:.
1881:.
1871:.
1861:.
1849:.
1845:.
1822:.
1812:.
1800:.
1796:.
1780:^
1762:.
1754:.
1725:.
1721:.
1696:.
1686:.
1674:.
1670:.
1647:.
1637:.
1625:.
1621:.
1598:.
1588:.
1576:.
1572:.
1549:.
1539:.
1525:.
1521:.
1509:^
1495:.
1481:.
1477:.
1432:.
1421:^
1395:.
1384:^
1362:.
1351:^
1333:.
1325:.
1313:.
1281:.
1270:^
1252:.
1248:.
1231:^
1213:.
1183:.
1158:.
1154:.
1128:.
1117:^
1095:.
1084:^
1061:.
1048:^
1030:.
1026:.
1013:^
995:.
984:^
962:.
951:^
925:.
910:^
888:.
873:^
850:.
835:^
813:.
798:^
762:.
699:.
659:,
590:.
517:48
505:12
313:EU
298:US
285:UK
269:CA
262:S4
256:AU
188:AU
156:US
6409::
6321:/
6290:)
6258:(
6058:)
6052:C
6048:B
6044:A
6042:(
5591:)
5028:)
5026:D
5022:C
5018:B
5014:A
5012:(
4809:)
4807:7
4803:6
4799:5
4795:4
4791:3
4787:2
4783:1
4781:(
4371:)
4365:9
4361:8
4357:6
4353:4
4345:1
4343:(
4290:)
4280:9
4276:8
4272:4
4264:1
4262:(
4185:)
4167:9
4163:8
4157:(
4155:7
4151:6
4147:5
4143:4
4139:3
4131:1
4129:(
4082:)
4072:8
4068:6
4064:5
4060:4
4056:3
4048:1
4046:(
4006:)
4000:4
3996:3
3992:2
3988:1
3986:(
3929:)
3923:2
3919:1
3917:(
3484:e
3477:t
3470:v
3131:/
2886:e
2879:t
2872:v
2800:)
2782:e
2775:t
2768:v
2751:.
2737::
2710:.
2688::
2661:.
2647::
2620:.
2587:.
2565::
2515:.
2493::
2463:.
2430:.
2406::
2398::
2392:7
2367:.
2336:.
2306:.
2276:.
2246:.
2219:.
2184:.
2153:.
2091:.
2060:.
2027:.
1997:.
1967:.
1914:.
1889:.
1865::
1857::
1851:7
1830:.
1808::
1802:9
1774:.
1740:.
1704:.
1682::
1655:.
1633::
1606:.
1584::
1578:8
1557:.
1533::
1527:9
1503:.
1483:4
1463:.
1452:.
1415:.
1378:.
1345:.
1321::
1297:.
1264:.
1225:.
1199:.
1169:.
1140:.
1111:.
1077:.
1042:.
1007:.
978:.
944:.
904:.
866:.
829:.
502:S
496:O
490:N
484:H
478:C
315::
300::
287::
258::
190::
117:/
71:)
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
